<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019110</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064330</org_study_id>
    <secondary_id>NCI-95-C-0154</secondary_id>
    <secondary_id>NCI-T94-0134N</secondary_id>
    <nct_id>NCT00019110</nct_id>
    <nct_alias>NCT00001441</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer</brief_title>
  <official_title>VACCINE THERAPY AND DETECTION OF IMMUNOLOGIC RESPONSES WITH HUMAN PAPILLOMAVIRUS 16 E6 AND E7 PEPTIDES IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED CERVICAL CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from certain human papillomaviruses may be able to help the body to
      kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of human papillomavirus vaccine therapy in
      treating patients who have advanced or recurrent cancer of the cervix, vagina, penis, anus,
      esophagus, or head and neck.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine whether endogenous cellular immunity to the viral oncoproteins human papilloma
           virus 16 (HPV16) E6 and E7 is present in patients with advanced or recurrent carcinoma
           of the cervix or other carcinomas that carry HPV16.

        -  Determine whether vaccination with antigen-presenting cells pulsed with synthetic
           peptide corresponding to the tumor's HPV16 E6 or E7 peptide can induce or boost patient
           cellular immunity to that particular peptide.

        -  Determine the type and characteristics of the cellular immunity generated in patients
           treated with this regimen.

        -  Determine the toxicity of this regimen in these patients.

        -  Determine the tumor response in patients treated with this regimen.

        -  Determine whether in vivo T cells generated specifically against HPV16 E6 or E7 peptide
           can be cloned and expanded in vitro against the corresponding peptide.

      OUTLINE: Patients are stratified according to disease category as defined by the following:

        -  Stratum A: Stage III cervical cancer not previously treated with appropriate
           radiotherapy; stage IV or recurrent cervical cancer; or other advanced tumors that
           harbor human papilloma virus 16 (HPV16) such as anogenital, esophageal, or head and neck
           cancers.

        -  Stratum B: Stage III cervical cancer previously treated with standard therapy with no
           evidence of residual disease. Vaccination in this group is given as adjuvant therapy.

      Patients are assigned to receive HPV E6 or E7 peptide by the principal investigator.
      Peripheral blood mononuclear cells (PBMC) (antigen presenting cells) are harvested and
      treated in vitro with sargramostim (GM-CSF) and pulsed with HPV16 E6 or E7. Patients receive
      vaccination with HPV16 E6 or E7 pulsed PBMC IV over 1-2 minutes during weeks 1, 3, 7, and 11
      for a total of 4 vaccinations. Treatment continues in the absence of disease progression or
      unacceptable toxicity. Patients who achieve complete response (CR) continue treatment for a
      maximum of 1 year past CR.

      Patients are followed at 1 month.

      PROJECTED ACCRUAL: A total of 40-46 patients (at least 28 patients for stratum A and 12 for
      stratum B) will be accrued for this study within 1-2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1995</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Anal Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Penile Cancer</condition>
  <condition>Vulvar Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human papillomavirus 16 E7 peptide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>synthetic human papillomavirus 16 E6 peptide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven stage III, IV, or recurrent carcinoma of the cervix or other
             tumor that carries human papilloma virus 16 (HPV16) such as other anogenital (vulvar,
             penile, and anal), esophageal, and head and neck cancers

          -  HLA-A2.1 positive

          -  Patients with tumors other than cervical cancer must have no other therapeutic options

          -  Fresh tissue or paraffin block available for HPV genome detection and typing (optional
             for cervical cancer)

          -  No history of CNS metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  Over 18

        Performance status:

          -  ECOG 0-1

        Life expectancy:

          -  More than 3 months

        Hematopoietic:

          -  WBC at least 2,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 2.0 mg/dL

          -  SGPT no greater than 4 times normal

        Renal:

          -  Creatinine no greater than 2.0 mg/dL

        Cardiovascular:

          -  No myocardial infarction within the past 6 months

          -  No New York Heart Association class III or IV heart disease

        Immunologic:

          -  No autoimmune disease, e.g.:

               -  Systemic lupus erythematosus

               -  Multiple sclerosis

               -  Ankylosing spondylitis

               -  HIV negative

          -  Responsive to 1 of the following skin test antigens:

               -  Mumps Trichophyton

               -  Candida Tetanus

        Other:

          -  No active infection requiring antibiotics

          -  No weight loss greater than 20% within the past 6 months

          -  No other active malignancy except basal cell skin cancer

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 4 weeks since prior immunotherapy and recovered

        Chemotherapy:

          -  At least 4 weeks since prior chemotherapy and recovered

        Endocrine therapy:

          -  At least 4 weeks since prior steroids and recovered

        Radiotherapy:

          -  At least 4 weeks since prior radiotherapy and recovered

        Surgery:

          -  Not specified

        Other:

          -  Recovered from the toxic effects of prior therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry L. Gause, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Memorial Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962-1956</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0587</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 1999</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <keyword>stage IV anal cancer</keyword>
  <keyword>recurrent anal cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>stage IIIA anal cancer</keyword>
  <keyword>stage IIIB anal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>stage III cervical cancer</keyword>
  <keyword>stage IV cervical cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage III vulvar cancer</keyword>
  <keyword>stage IVB vulvar cancer</keyword>
  <keyword>recurrent vulvar cancer</keyword>
  <keyword>stage III penile cancer</keyword>
  <keyword>stage IV penile cancer</keyword>
  <keyword>recurrent penile cancer</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>metastatic squamous neck cancer with occult primary squamous cell carcinoma</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III basal cell carcinoma of the lip</keyword>
  <keyword>stage III verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage III mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage III adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV basal cell carcinoma of the lip</keyword>
  <keyword>stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage IV mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent basal cell carcinoma of the lip</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>stage III salivary gland cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Penile Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

